- $12.67bn
- $12.37bn
- $363.71m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 44.4 | ||
| Price to Tang. Book | 139.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 34.84 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -50.83% | ||
| Return on Equity | n/a | ||
| Operating Margin | -241.47% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 164.41 | 188.46 | 245.36 | 305.21 | 363.71 | 464.83 | 1,001.53 | 21.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Insmed Incorporated is a global biopharmaceutical company. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
Directors
- William Lewis CHM (52)
- Sara Bonstein CFO (40)
- Roger Adsett COO (52)
- Michael Smith SVP (44)
- John Soriano CCO (59)
- Martina Flammer OTH (57)
- S. Nicole Schaeffer OTH (52)
- David Brennan LED (67)
- Alfred Altomari IND (62)
- Elizabeth Anderson IND (63)
- Clarissa Desjardins IND (54)
- Steinar Engelsen IND (70)
- Leo Lee IND (51)
- David McGirr IND (66)
- Carol Schafer IND (57)
- Melvin Sharoky IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 29th, 1999
- Public Since
- February 15th, 1991
- No. of Shareholders
- 148
- No. of Employees
- 1,271
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 181,820,010
- Address
- 700 Us Highway 202/206, BRIDGEWATER, 08807
- Web
- https://insmed.com/
- Phone
- +1 9089779900
- Contact
- Bryan Dunn
- Auditors
- Ernst & Young LLP
Upcoming Events for INSM
Q1 2025 Insmed Inc Earnings Release
Insmed Inc Annual Shareholders Meeting
Q2 2025 Insmed Inc Earnings Release
Similar to INSM
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Insmed share price?
As of Today at 21:20 UTC, shares in Insmed are trading at $69.69. This share price information is delayed by 15 minutes.
How has the Insmed share price performed this year?
Shares in Insmed last closed at $69.69 and the price had moved by +179.65% over the past 365 days. In terms of relative price strength the Insmed share price has outperformed the S&P500 Index by +158.13% over the past year.
What are the analyst and broker recommendations for Insmed?
The overall consensus recommendation for Insmed is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Insmed dividend yield?
Insmed does not currently pay a dividend.
Does Insmed pay a dividend?
Insmed does not currently pay a dividend.
When does Insmed next pay dividends?
Insmed does not currently pay a dividend.
How do I buy Insmed shares?
To buy shares in Insmed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Insmed?
As of the previous close price of $69.69, shares in Insmed had a market capitalisation of $12.67bn.
Where are Insmed shares listed?
Here are the trading details for Insmed:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: INSM
What kind of share is Insmed?
Based on an overall assessment of its quality, value and momentum Insmed is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Insmed share price forecast for 2025?
The analyst consensus target price for shares in Insmed is $95.69. That is 37.31% above the last closing price of $69.69.
Analysts covering Insmed currently have a consensus Earnings Per Share (EPS) forecast of -$5.34 for the next financial year.
Find out moreWhat is the trend in the Insmed share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Insmed. Over the past six months, its share price has outperformed the S&P500 Index by +3.51%.
As of the last closing price of $69.69, shares in Insmed were trading -5.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Insmed PE Ratio?
The Insmed PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $69.69.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Insmed?
Insmed's management team is headed by:
- William Lewis - CHM
- Sara Bonstein - CFO
- Roger Adsett - COO
- Michael Smith - SVP
- John Soriano - CCO
- Martina Flammer - OTH
- S. Nicole Schaeffer - OTH
- David Brennan - LED
- Alfred Altomari - IND
- Elizabeth Anderson - IND
- Clarissa Desjardins - IND
- Steinar Engelsen - IND
- Leo Lee - IND
- David McGirr - IND
- Carol Schafer - IND
- Melvin Sharoky - IND